Table 3 Meta-analysis results using reported multivariable adjusted data
Analysis for adjusted mortality data | Studies (N) | Adjusted HR (95% CI) |
|---|---|---|
Totally high-risk patient populations | 5 | 4.67 (2.18, 9.99); I2 = 77.7% |
Low risk of bias | 4 | 4.62 (1.87, 11.42); I2 = 83.3% |
CS infection comparator | 2 | 2.07 (1.22, 3.53); I2 = 0.0% |
No CR infection comparator | 2 | 8.63 (4.12, 18.08); I2 = 31.6% |
No infection comparator | 1 | 6.92 (3.24, 14.79) |
Longer-term (> 30 days) mortality | 4 | 6.67 (3.88, 11.49); I2 = 0.0% |
Italy | 2 | 4.53 (0.78, 26.20); I2 = 93.3% |
USA | 3 | 5.19 (2.99, 9.01); I2 = 0.0% |
Partially and totally high-risk patient populations | 8 | 3.38 (1.93, 5.94); I2 = 76.0% |
Low risk of bias | 6 | 3.87 (2.10, 7.13); I2 = 76.9% |
CS infection comparator | 4 | 1.93 (1.24, 2.99); I2 = 8.2% |
No CR infection comparator | 2 | 8.63 (4.12, 18.08); I2 = 31.6% |
No infection comparator | 2 | 4.08 (1.56, 10.65); I2 = 76.5% |
In-hospital/≤30-day mortality | 4 | 2.05 (1.39, 3.02); I2 = 16.9% |
Longer-term (> 30 days) mortality | 4 | 6.67 (3.88, 11.49); I2 = 36.6% |
CRKP studies only | 7 | 3.45 (1.83, 6.51); I2 = 79.3% |
Studies reporting HR | 6 | 4.17 (2.23, 7.80); I2 = 76.6% |
Studies reporting OR | 2 | 1.71 (0.60, 4.82); I2 = 60.1% |
Italy | 2 | 4.53 (0.78, 26.20); I2 = 93.3% |
USA | 6 | 3.02 (1.79, 5.08); I2 = 54.2% |